Omniox's Series C Round

Omniox raised a round of funding on July 27, 2016.

Omniox is an IND-stage biotherapeutics company developing OMX as a broad-acting cancer immunotherapy. OMX is engineered to deliver oxygen safely into hypoxic, immunosuppressive tumor microenvironments…

Articles about Omniox's Series C Round: